News | Novartis
Forced into a virtual world': Novartis brings trials to the patient | Fierce Biotech
News | Novartis
Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women | Novartis
News | Novartis
Bristol Myers Squibb takes over closing Novartis Libertyville plant | Crain's Chicago Business
Google teams up with Novartis to bring smart contact lenses to market
Novartis eyes 7-day CAR-T process, not allo - BioProcess InsiderBioProcess International
Novartis Institutes for BioMedical Research Internships | Announce | University of Nebraska-Lincoln
Novartis signs up for Google smart lens | Nature Biotechnology
GSK/Novartis transaction | GSK India
Media Library | Novartis
Media Library | Novartis
Why Novartis Shares Are Trading Higher Premarket Today
Media Contacts | Novartis Australia
Novartis-logo | Allergy & Asthma Network
Novartis Increases Growth Potential Through Integration of Alcon - Review of Optometric Business
Former CEO of Novartis-Sandoz (South Africa) to Lead AAT Research's Global Expansion | Business Wire
Media Contacts | Novartis India
Novartis and UC Berkeley Extend Alliance to Tackle 'Undruggable' Disease Targets and Discover New Therapeutic Modalities | Business Wire
Contact Lenses From Sam's Club Contacts
Product Safety Notices | Sandoz US
Media Library | Novartis
Novartis (NVS) Q3 2022 Earnings Call Transcript | The Motley Fool
Novartis announces eXcellence in Ophthalmology Vision Award 2014 winners for outstanding eye health projects
News | Novartis
